Cryofocus Medtech (Shanghai) Co., Ltd. filed its Monthly Return for the period ended 31 May 2026, confirming that the company’s equity structure remained unchanged during the month.

Total registered share capital stood at 244.71 million shares with a par value of RMB 1 each. The mix comprises: • 149.03 million H shares listed in Hong Kong; • 95.67 million unlisted domestic shares.

No new shares were issued, cancelled, or repurchased, and the company held zero treasury shares at month-end.

Cryofocus affirmed compliance with the Hong Kong Stock Exchange’s minimum public-float requirement of 25% for its H-share class. There were no outstanding share options, warrants, convertible instruments, or other agreements that could dilute the share base, and the company does not have Hong Kong Depositary Receipts.

The return, dated 2 June 2026, was signed by Director Zhu Jun.